Can Women with Grade 3 Cervical Erosion Receive the 9-Valent HPV Vaccine?

Cervical ectropion—commonly, though inaccurately, referred to as “cervical erosion”—is a benign, physiological condition in which columnar epithelium extends onto the ectocervix, giving the appearance of redness or “erosion” during speculoscopy. It is not a disease, nor is it associated with infection, precancerous change, or increased cancer risk. The term “degree three” (or “grade three”) has no standardized clinical meaning in modern gynecology and is not used in evidence-based guidelines; it reflects outdated terminology that conflates normal anatomical variation with pathology.

Human papillomavirus (HPV) vaccination—including the 9-valent HPV vaccine—is recommended based on age, immunocompetence, and prior exposure—not on the presence or appearance of cervical ectropion. The 9-valent vaccine protects against nine high- and low-risk HPV types (6, 11, 16, 18, 31, 33, 45, 52, and 58) and is approved for individuals aged 9 through 45 years. Cervical ectropion does not contraindicate HPV vaccination. In fact, vaccination remains clinically appropriate—and strongly encouraged—for eligible individuals regardless of cervical appearance, colposcopic findings, or prior cytology results.

Patients diagnosed with cervical ectropion should be reassured that the condition requires no treatment unless symptomatic (e.g., persistent postcoital bleeding or mucopurulent discharge). Management focuses on patient education and routine cervical cancer screening per established guidelines (e.g., co-testing or primary HPV testing), independent of ectropion status. Vaccination decisions should be guided by current national immunization schedules—not by misinterpreted cervical findings.